Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aligos Therapeutics (ALGS) Operating Income (2021 - 2025)

Aligos Therapeutics' Operating Income history spans 5 years, with the latest figure at $61.2 million for Q4 2025.

  • For Q4 2025, Operating Income rose 397.41% year-over-year to $61.2 million; the TTM value through Dec 2025 reached -$5.0 million, up 94.37%, while the annual FY2025 figure was -$5.0 million, 94.37% up from the prior year.
  • Operating Income reached $61.2 million in Q4 2025 per ALGS's latest filing, up from -$28.4 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $61.2 million in Q4 2025 to a low of -$37.9 million in Q4 2021.
  • Average Operating Income over 5 years is -$20.4 million, with a median of -$22.4 million recorded in 2022.
  • The largest YoY upside for Operating Income was 397.41% in 2025 against a maximum downside of 40.88% in 2025.
  • A 5-year view of Operating Income shows it stood at -$37.9 million in 2021, then skyrocketed by 40.23% to -$22.7 million in 2022, then decreased by 14.62% to -$26.0 million in 2023, then grew by 20.9% to -$20.6 million in 2024, then soared by 397.41% to $61.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Operating Income are $61.2 million (Q4 2025), -$28.4 million (Q3 2025), and -$18.6 million (Q2 2025).